Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Harry P Erba

Showing results (61-70 of 123) with videos related to

Pageof 13
Sort By:
Leukemia & Lymphoma|October 13, 2022
Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOGMegan Othus, Ian Thomas, Xu Wang, et al.
British Journal of Haematology|November 19, 2015
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup studyThomas Prebet, Zhuoxin Sun, Rhett P Ketterling, et al.
Blood Advances|April 8, 2026
Quizartinib in newly diagnosed patients with FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-FirstMark J Levis, Harry P Erba, Pau Montesinos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2025
Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition With Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild Type Acute Myeloid LeukemiasWeiguo Zhang, Li Li, Muharrem Muftuoglu, et al.
Haematologica|April 6, 2023
Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research NetworkChristina M Termini, Anna Moseley, Megan Othus, et al.
Blood Advances|July 15, 2022
Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemiaLori Muffly, Jun Yin, Sawyer Jacobson, et al.
Hematological Oncology|April 22, 2023
A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemiaBrian A Jonas, Jing-Zhou Hou, Gail J Roboz, et al.
Leukemia|March 27, 2021
Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplantCourtney D DiNardo, Eytan M Stein, Arnaud Pigneux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2014
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905Thomas Prebet, Zhuoxin Sun, Maria E Figueroa, et al.
Blood Advances|November 2, 2022
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemiaAnjali S Advani, Anna Moseley, Kristen M O'Dwyer, et al.
Pageof 13

Showing results (61-70 of 123) with videos related to

Sort By:
Pageof 13
Leukemia & Lymphoma|October 13, 2022
Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOGMegan Othus, Ian Thomas, Xu Wang, et al.
British Journal of Haematology|November 19, 2015
Azacitidine with or without Entinostat for the treatment of therapy-related myeloid neoplasm: further results of the E1905 North American Leukemia Intergroup studyThomas Prebet, Zhuoxin Sun, Rhett P Ketterling, et al.
Blood Advances|April 8, 2026
Quizartinib in newly diagnosed patients with FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-FirstMark J Levis, Harry P Erba, Pau Montesinos, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2025
Synergistic Activity of Combined FLT3-ITD and MDM2 Inhibition With Quizartinib and Milademetan in FLT3-ITD Mutant/TP53 Wild Type Acute Myeloid LeukemiasWeiguo Zhang, Li Li, Muharrem Muftuoglu, et al.
Haematologica|April 6, 2023
Examining the impact of age on the prognostic value of ELN-2017 and ELN-2022 acute myeloid leukemia risk stratifications: a report from the SWOG Cancer Research NetworkChristina M Termini, Anna Moseley, Megan Othus, et al.
Blood Advances|July 15, 2022
Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemiaLori Muffly, Jun Yin, Sawyer Jacobson, et al.
Hematological Oncology|April 22, 2023
A phase 1b study of venetoclax and alvocidib in patients with relapsed/refractory acute myeloid leukemiaBrian A Jonas, Jing-Zhou Hou, Gail J Roboz, et al.
Leukemia|March 27, 2021
Outcomes of patients with IDH1-mutant relapsed or refractory acute myeloid leukemia receiving ivosidenib who proceeded to hematopoietic stem cell transplantCourtney D DiNardo, Eytan M Stein, Arnaud Pigneux, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 26, 2014
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905Thomas Prebet, Zhuoxin Sun, Maria E Figueroa, et al.
Blood Advances|November 2, 2022
Dasatinib/prednisone induction followed by blinatumomab/dasatinib in Ph+ acute lymphoblastic leukemiaAnjali S Advani, Anna Moseley, Kristen M O'Dwyer, et al.
Pageof 13